The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis
Open accessAbstract
Screening for new antimicrobial agents is routinely conducted only against actively replicating bacteria. However, it is now widely accepted that a physiological state of nonreplicating persistence (NRP) is responsible for antimicrobial tolerance in many bacterial infections. In tuberculosis, the key to shortening the 6-month regimen lies in targeting this NRP subpopulation. Therefore, a high-throughput, luminescence-based low-oxygen-recovery assay (LORA) was developed to screen antimicrobial agents against NRP Mycobacterium tuberculosis. M. tuberculosis H 37 Rv containing a plasmid with an acetamidase promoter driving a bacterial luciferase gene was adapted to low oxygen conditions by extended culture in a fermentor with a 0.5 headspace ratio. The MICs of 31 established antimicrobial agents were determined in microplate cultures maintained under anaerobic conditions for 10 days and, for comparative purposes, under aerobic conditions for 7 days. Cultures exposed to drugs under anaerobic conditions followed by 28 h of “recovery” under ambient oxygen produced a luminescent signal that was, for most compounds, proportional to the number of CFU determined prior to the recovery phase. No agents targeting the cell wall were active against NRP M. tuberculosis , whereas drugs hitting other cellular targets had a range of activities. The calculated Z ′ factor was in the range of 0.58 to 0.84, indicating the suitability of the use of LORA for high-throughput assays. This LORA is sufficiently robust for use for primary high-throughput screening of compounds against NRP M. tuberculosis .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Collins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Self-citationBetts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M., et al. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.362-366.1998 · Cited by 964 · cited 1×
“Previous attempts in our laboratory to use Alamar Blue reduction (12, 18) or green (or red) fluorescent protein expression (9) as a viability endpoint following anaerobic incubation required up to 1 week of aerobic recovery to obtain an adequate signal, a time period that seriously compromised data interpretation (dat…”
MethodSelf-citationPark, H., Guinn, K. M., Harrell, M. I., Liao, R., Voskuil, M. I., Tompa, M., Schoolnik, G. K., & Sherman, D. R. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03474.x · Cited by 712
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Tuberculosis — metabolism and respiration in the absence of growth
Boshoff, H. I. M., & Barry, C. E. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1065 · Cited by 448
Dormancy ofMycobacterium tuberculosis and latency of disease
Wayne, L. G. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02111491 · Cited by 387
Wayne, L. G., & Lin, K. Y. (1982) · Infection and Immunity · doi:10.1128/iai.37.3.1042-1049.1982 · Cited by 324
Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., & Orme, I. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2294-2301.2005 · Cited by 306
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis
Wayne, L. G., & Sramek, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2054 · Cited by 295
Changsen, C., Franzblau, S. G., & Palittapongarnpim, P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3682-3687.2003 · Cited by 275
Self-citationMycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy
Boon, C., & Dick, T. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.24.6760-6767.2002 · Cited by 251
In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis
Falzari, K., Zhu, Z., Pan, D., Liu, H., Hongmanee, P., & Franzblau, S. G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1447-1454.2005 · Cited by 207
Self-citationGene expression profile of Mycobacterium tuberculosis in a non-replicating state
Muttucumaru, D. G. N., Roberts, G., Hinds, J., Stabler, R. A., & Parish, T. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.12.006 · Cited by 205
Hu, Y., Coates, A. R. M., & Mitchison, D. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.653-657.2003 · Cited by 187
Hu, Y., Mangan, J. A., Dhillon, J., Sole, K. M., Mitchison, D. A., Butcher, P. D., & Coates, A. R. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.22.6358-6365.2000 · Cited by 181
Assessment of Immunity to Mycobacterial Infection with Luciferase Reporter Constructs
Snewin, V. A., Gares, M.-P., ÓGaora, P., Hasan, Z., Brown, I. N., & Young, D. B. (1999) · Infection and Immunity · doi:10.1128/iai.67.9.4586-4593.1999 · Cited by 177
New perspectives on natural products in TB drug research
Pauli, G. F., Case, R. J., Inui, T., Wang, Y., Cho, S., Fischer, N. H., & Franzblau, S. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.004 · Cited by 159
Self-citationLuminescence-based detection of activity of starved and viable but nonculturable bacteria
Duncan, S. H., Glover, L. A., Killham, K., & Prosser, J. I. (1994) · Applied and Environmental Microbiology · doi:10.1128/aem.60.4.1308-1316.1994 · Cited by 136
Differential Antibiotic Susceptibilities of Starved Mycobacterium tuberculosis Isolates
Xie, Z., Siddiqi, N., & Rubin, E. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4778-4780.2005 · Cited by 136
Use of Aminoglycosides in Treatment of Infections Due to Intracellular Bacteria
Maurin, M., & Raoult, D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.2977-2986.2001 · Cited by 131
Design, Synthesis, and SAR Studies of Mefloquine‐Based Ligands as Potential Antituberculosis Agents
Jayaprakash, S., Iso, Y., Wan, B., Franzblau, S. G., & Kozikowski, A. P. (2006) · ChemMedChem · doi:10.1002/cmdc.200600010 · Cited by 107
Self-citationJames, B. W., Williams, A., & Marsh, P. D. (2000) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.2000.01020.x · Cited by 97
Florczyk, M. A., McCue, L. A., Stack, R. F., Hauer, C. R., & McDonough, K. A. (2001) · Infection and Immunity · doi:10.1128/iai.69.9.5777-5785.2001 · Cited by 95
Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
Wade, M. M., & Zhang, Y. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45639-0 · Cited by 80
ICAT-based comparative proteomic analysis of non-replicating persistent Mycobacterium tuberculosis
Cho, S., Goodlett, D. R., & Franzblau, S. G. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.10.002 · Cited by 67
Self-citationForeword from the Co-Editor-in-Chief
Brennan, P. J. (2001) · Tuberculosis · doi:10.1054/tube.2001.0288 · Cited by 64
Capreomycin is active against non-replicating M. tuberculosis
Heifets, L. B., Simon, J., & Pham, V. H. (2005) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-4-6 · Cited by 63
Dhillon, J., Lowrie, D. B., & Mitchison, D. A. (2004) · BMC Infectious Diseases · doi:10.1186/1471-2334-4-51 · Cited by 57
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.
Dhillon, J., Allen, B. W., Hu, Y., Coates, A. R. M., & Mitchison, D. A. (1998) · PubMed · Cited by 57
Burman, W. J. (1997) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40137-5 · Cited by 32
Cited by
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
A replication clock for Mycobacterium tuberculosis
Gill, W. P., Harik, N. S., Whiddon, M. R., Liao, R. P., Mittler, J. E., & Sherman, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1915 · Cited by 341
Metadata
- Authors
- Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., & Franzblau, S. G.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-04
- Volume
- 51
- Issue
- 4
- Pages
- 1380-1385
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2100383399
- Cited by
- 292
- References
- 34
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.